By Shawn Hauser
May 29, 2024
We are at a historic and critical moment for cannabis reform, as the DOJ and HHS/FDA have proposed rescheduling cannabis to Schedule III. The DEA is accepting public comments until July 22, 2024 via the Federal eRulemaking Portal, so now is the time to take action and make your voice heard!
By Jason Adelstone
May 21, 2024
The DEA published its proposed rule to move marijuana from schedule I to schedule III on May 21, and the 60-day public comment period has officially opened. The DEA also published an opinion from the Office of Legal counsel that provides a thorough analysis supporting why placing marijuana in schedule III is appropriate and legally justified. Read this insight for a high-level overview of the proposed rule and the OLC Opinion.
By Jason Adelstone
May 20, 2024
In a recent House Committee meeting with DEA Administrator Anne Milgram, Rep. Andrew S. Clyde voiced his opposition to removing marijuana from Schedule I based on public safety reasons, but then contradicted himself by stating marijuana is “not as dangerous as some of the others we have talked about” (the meeting focused primarily on fentanyl’s harms to communities). This blog post addresses the false narratives and misconceptions that opponents of cannabis reform continue to promote.
May 7, 2024
On May 8, Vicente’s director of economics and research, Andrew Livingston, is joining Rootwurks for a webinar to break down what it will mean for the cannabis industry now that the DEA is making moves to reclassify cannabis into schedule III—and what work for legalization remains to be done. Register now!
By Shawn Hauser
May 7, 2024
Vicente LLP partner Shawn Hauser argues in a new Marijuana Moment op-ed that the federal decision to reschedule cannabis is “a historic and critically important shift”—with the government “finally (and officially) recognizing the efficacy and safety of cannabis for medical use.”
May 3, 2024
Watch this special briefing featuring Vicente LLP leaders who have been deeply immersed in the federal scheduling issue, along with Mitzi Keating, a CPA and partner at Citrin Cooperman.
By Jason Adelstone
Apr 29, 2024
After listening to the House Oversight and Accountability Committee Hearing with the Commissioner of the FDA on April 11, one conclusion was reinforced—opponents of marijuana reform are misinformed and rely on misstating facts to support their position. Those against moving marijuana into schedule III are making their voices heard, but almost universally, those voices simply do not understand what schedule III would mean.
By Jason Adelstone
Jan 30, 2024
On August 29, 2023, the Department of Health and Human Services (“HHS”) sent the Drug Enforcement Administration (“DEA”) its recommendation to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”). Since then, the marijuana industry has waited in suspense for the DEA to make the final call as to what schedule marijuana will be placed. Read this Insights post that outlines the complex process of marijuana rescheduling in the US and outlines the key steps involved, from rule publication to review and final rule, emphasizing the critical role of stakeholder engagement in securing a Schedule III classification.
Nov 10, 2023
Federal and international law and policy insights, news and events from Vicente LLP.
By Jason Adelstone
Nov 6, 2023
While the cannabis industry in the United States awaits a marijuana scheduling decision from the DEA, many countries around the world continue to move forward with liberalizing their cannabis policies as a superior method of promoting the health and welfare of their citizens. In this blog post, we’ll take a closer look at five countries poised to make waves in the cannabis landscape in 2024, including Germany, Thailand, Colombia, the Czech Republic, and Switzerland.
Oct 26, 2023
This recorded session features members of Vicente LLP’s Federal and International Law and Policy practice group and London cannabis attorney Robert Jappie of Fieldfisher sharing insights into what’s happening with cannabis and hemp-derived cannabinoids across the pond and opportunities for US operators and investors.
By David M. Ullian, Gabriel Amatruda
Oct 5, 2023
Public support for medical cannabis in North Carolina is quite strong and despite being one of only a few states that have legalized medical or adult use, cannabis is finally making headway in the Tar Heel State. Read this article to learn about recent cannabis and hemp developments in NC, including legislation and the Eastern Band of Cherokee Indians’ vote to legalize adult-use cannabis.
Oct 4, 2023
Watch this special briefing where Vicente LLP leaders share insights on the impacts of the HHS recommendation to reschedule cannabis and outline the road ahead.
By Shane Pennington
Nov 9, 2022
What outcomes are possible from the impending administrative process to reconsider cannabis’s schedule I status? What are the implications of those various possible outcomes? And how should we all proceed in light of it all?
By Shane Pennington
Oct 21, 2022
To appreciate the gravity of the President’s scheduling directive and what could happen next, you need to understand (1) how the administrative process the President has set in motion will actually work and (2) how the agencies in charge have used it to affirm and reaffirm cannabis’s schedule I1 status repeatedly throughout the Comprehensive Drug Abuse Prevention and Control Act of 1970’s (“CSA”) history. Those topics are covered in this article.
By Jennifer Flanagan
Aug 26, 2022
Jennifer Flanagan writes for the Worcester Telegram & Gazette, reflecting on the Commonwealth's first major cannabis reform legislation since Massachusetts established a regulated adult-use cannabis market.
By Charles Alovisetti
Jan 25, 2021
Like anything in the cannabis industry, getting a debt deal done requires navigating unique regulatory challenges. Here are seven regulatory considerations that cannabis borrowers and lenders should keep in mind when pursuing a debt transaction.
By Charles Alovisetti, Elliot Choi, Sahar Ayinehsazian
Sep 18, 2020
Raising private capital continues to be a challenge for the nascent cannabis industry, but there are proactive steps companies can take to maximize the chance of a successful raise.